VVOSHealthcare · Medical DevicesThe 3 Wall Street analysts covering Vivos Therapeutics, Inc. hold a median 12-month price target of $2.5 — +755.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 25 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Vivos Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (95): Smaller than most of the companies we track.
Issuance (10): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on VVOS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +755.3% from it.
Of the 15 most recent actions, 1 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 4 June 2026 | Ascendiant Capital | Maintains | Buy | $3.00 → $3.10 |
| 22 Apr 2026 | Ascendiant Capital | Maintains | Buy | — |
| 17 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 3 Dec 2025 | Ascendiant Capital | Maintains | Buy | — |
| 17 Nov 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 9 Sept 2025 | Ascendiant Capital | Maintains | Buy | — |
| 15 Apr 2025 | Ascendiant Capital | Maintains | Buy | — |
| 20 Nov 2024 | Ascendiant Capital | Reiterates | Buy | — |
| 19 Nov 2024 | Alliance Global Partners | Maintains | Buy | — |
| 20 Aug 2024 | Ascendiant Capital | Maintains | Buy | — |
| 17 Jan 2023 | Ascendiant Capital | Initiates | Buy | $2.50 |
| 13 Aug 2021 | Roth Capital | Maintains | Buy | $11 → $10 |
| 18 May 2021 | Roth Capital | Maintains | Buy | $12 → $11 |
| 11 Jan 2021 | Craig-Hallum | Initiates | Buy | — |
| 5 Jan 2021 | Roth Capital | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VVOS appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 77% of US stocks
Cheaper than 90% of US stocks
Cheaper than 96% of US stocks
Cheaper than 66% of US stocks
Higher than 81% of US stocks
Higher than 80% of US stocks
Higher than 73% of US stocks
Higher than 14% of US stocks
Higher than 5% of US stocks
Higher than 1% of US stocks
Higher than 7% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Vivos Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Vivos Therapeutics has opened a new sleep testing and treatment facility in Nevada to address growing patient demand for sleep apnea testing and treatment.
Why it matters — The expansion signals Vivos is scaling its service capacity to meet increasing patient demand for sleep apnea care.
Vivos Therapeutics reported a Q2 loss of $0.31 per share, narrower than the Zacks Consensus Estimate of a $0.42 loss and improved from the $0.55 loss recorded a year earlier.
Why it matters — The loss came in better than analyst expectations, and the year-over-year improvement may signal progress in the company's financial performance.
Vivos Therapeutics, Inc. (VVOS) published the transcript of its Q2 2026 earnings call, as reported by Seeking Alpha. The item consists solely of the earnings call transcript for the second quarter of fiscal 2026.
Why it matters — VVOS watchers can review the management commentary from the company's Q2 2026 earnings call presented in the transcript.
Vivos Therapeutics reported its financial results and operating highlights for the three and six months ended June 30, 2026, with the quarter highlighted by steadily increasing patient demand for its differentiated array of obstructive sleep apnea (OSA) treatments. The company also announced it would host a conference call at 5:00 pm ET that day.
Why it matters — The report provides an update on Vivos' Q2 2026 financial performance and signals growing demand for its OSA treatment offerings, key indicators for investors watching the company's commercial progress.
Vivos Therapeutics announced it plans to release its second quarter 2026 financial results after market close on Friday, August 14, 2026, and to hold a conference call to discuss them.
Why it matters — VVOS watchers will be looking to the company's second quarter financial results and conference call for the latest update on its sleep-related breathing disorder business.
The 3 Wall Street analysts covering Vivos Therapeutics, Inc. have a median 12-month price target of $2.5, with estimates ranging from $0.75 to $3.1. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Vivos Therapeutics, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Vivos Therapeutics, Inc. 25 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Vivos Therapeutics, Inc. ranks 25 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (95 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +755.3% from the last close, and Ticker Nerd's factor model ranks Vivos Therapeutics, Inc. 25 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Vivos Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VVOS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $0.75 to $3.1 over the next 12 months.
Vivos Therapeutics, Inc. returned -93.6% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Vivos Therapeutics, Inc. is a medical technology company that concentrates on addressing sleep apnea through innovative treatment solutions.
The most recent item we track (GlobeNewsWire, 20 Aug 2026): "Vivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and Treatment". Vivos Therapeutics has opened a new sleep testing and treatment facility in Nevada to address growing patient demand for sleep apnea testing and treatment.
Vivos Therapeutics, Inc. is a medical technology company that concentrates on addressing sleep apnea through innovative treatment solutions. Primarily known for its proprietary systems and devices, the company offers a non-surgical approach designed to improve airway function and alleviate symptoms for patients suffering from obstructive sleep apnea (OSA), a common and often undiagnosed condition linked to various health issues. Operating at the intersection of medical devices and dental care, Vivos provides its solutions primarily to healthcare professionals, enabling them with tools and training necessary to effectively manage and treat sleep disorders. This focus on a non-invasive methodology has positioned Vivos as a notable player in the sleep disorder treatment market. Its approach not only aims to provide relief for individuals but also reduces dependency on traditional continuous positive airway pressure (CPAP) machines. Vivos Therapeutics plays a significant role in enhancing patient care within the healthcare sector by bridging the gap between dentistry and medicine, helping to raise awareness and offer alternative treatments for sleep-related breathing disorders.
CEO Mr. R. Kirk Huntsman · 268 employees · United States · https://www.vivos.com